Priority Issue 1

Fulfill Unmet Medical Needs

Target for 2030

Develop and disseminate new treatments based on regenerative medicine and cell therapy.

The Fujifilm Group is striving forward in the development and dissemination of new therapies for unmet medical needs, where effective treatment is still to be found. Fujifilm possesses the highly functional material synthetic technologies and engineering skills that we have gained through our photographic film development and production, including advanced nano dispersion technology, analysis technology, and production engineering technologies. We are actively seeking synergetic collaborations with business partners who also possess superior technologies, in order to develop new solutions in regenerative medicine and cell therapy and improve accessibility to such advanced treatments.

Outline of Activities in FY2018

[Target] Develop new treatment solutions (1 Regenerative medicine, 2 Infectious disease treatment, 3 Central nervous system)

- 1 Autologous cultured epidermis JACE® was approved for inclusion within national health insurance coverage as regenerative care for hereditary epidermolysis bullosa, a refractory genetic disease.
- 1 Applied for manufacturing and marketing approval of autologous cultured corneal epithelium (EYE-01M), the first regenerative medical product in ophthalmic field in Japan.
- 1 Received the Prize for Science and Technology under a FY2019 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology for "Development of Autologous Cultured Epidermis."
- 2 Obtained an imported drug license in China for the oral synthetic quinolone antibacterial agent, which is mainly for respiratory tract infections, such as pneumonia.



Autologous cultured epidermis JACE® (left) and autologous cultured corneal epithelium: EYE-01M (right)

- 2 Applied for manufacturing and marketing approval in Japan for a new antibacterial agent for treatment for infectious diseases in otorhinolaryngology, such as otitis media and sinusitis.
- 2 Launched Japan's first oral antifungal agent miconazole ORAVI® Mucoadhesive Tablets 50 mg for oropharyngeal candidiasis treatment.
- 3 Started the phase II clinical trials of a new drug candidate that accelerates rehabilitation after strokes.

[Target] Improve accessibility to new treatment solutions (4 Contribution through contract development and manufacturing, 5 Contribution through development and dissemination of products that support advanced treatments)

- 4 Acquired a large-scale biologics manufacturing site from a major US biopharmaceutical* company, Biogen.
- 4 Significantly shortened the development period of biopharmaceuticals down to 34 weeks, the shortest in the CDMO industry.
- 4 Developed a high-performance and highly efficient fully integrated continuous production system that controls processes from cultivation to purification.
- 5 Launched new product iCell® Microglia, an iPSC-derived neural cell type, contributing to new drug evaluation in human biology, mainly for drugs for neurological diseases, such as for Alzheimer's diseases.
- 5 FUJIFILM Wako Bio Solutions Corporation, our new company, started new subcontract services in new drug development support and inspection.

* Biopharmaceuticals: Pharmaceutical products utilizing biological particles, such as proteins, that provide effects unachievable by conventional chemically synthesized small-molecule drugs. Such biopharmaceuticals include insulin, vaccines, and antibody drugs. Antibody drugs utilize antibodies used by the immune system to protect our bodies from abnormal organisms, such as viruses and cancer cells, by recognizing them selectively.

Future Activities and Targets

- Introduce regenerative medicine products to the market, expand their application and improve contract manufacturing for these products.
- Accelerate the development of new drug pipelines.
- Expand contract manufacturing for biopharmaceuticals.
- Develop and disseminate cell culture medium or relevant manufacturing technologies that support advanced biomedical treatments (gene therapy, etc.).

Development of Regenerative Medicine that Enables "Complete Cure"

Regenerative medicine is expected to be a solution to treat diseases that currently do not have effective treatments. Aiming to be a leading company in regenerative medicine field, the Fujifilm Group has actively conducted R&D and M&A. Such efforts have made us the only company in the world that possesses the tissue engineering triad necessary for regenerative medicine—stem cells, scaffolds, and cell culture medium/cytokine, and we are continuing these efforts as we expand this area of our business.